First Ozempic-style PILL helps dieters shed over 1st – and could be cheaper option than jabs
A DAILY weight loss pill that works like Ozempic has passed a full clinical trial for the first time. Orforglipron is made by Lilly which manufactures the ‘King Kong’ of fat jabs, Mounjaro. AlamyA daily weight loss pill could work like Ozempic (stock image)[/caption] A trial has found diabetic patients taking it without dieting lost … Read more
STAT+: Daily pill from Eli Lilly helps patients control blood sugar, lose weight, Phase 3 study shows
A daily pill from Eli Lilly helped patients with type 2 diabetes improve their blood sugar and shed weight, the company said Thursday, results that could propel the next-generation treatment onto the market. The drug, orforglipron, produced results that were nearly comparable to the benefits of available GLP-1 drugs, which are weekly injectable treatments. Companies … Read more
Lilly’s First Pill for Diabetes, Weight Loss Shows Positive Study Results
The drug helped lower blood sugar and cut an average of 16 pounds The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and even reduce weight, bringing an oral …
Lilly’s oral GLP-1 drug delivers Ozempic-like efficacy in phase 3 diabetes trial
Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. The phase 3 study linked the oral GLP-1 drug orforglipron to similar reductions in blood glucose and body weight to Novo Nordisk’s injectable blockbuster, although the figures are down on Lilly’s midphase data.
GLP-1 Drugs May Protect Against Alzheimer’s
University of Florida A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects…
GLP-1 Weight-Loss Drugs May Guard Against Dementia
submitted by /u/Diamond-Is-Not-Crash [link] [comments]
Pfizer Pulls Plug On Weight Loss Pill Amid Liver Damage Fears
Pfizer announced it is ending its development of its experimental oral GLP-1 drug to treat obesity, the company said on Monday, after a patient in a trial suffered a liver injury potentially caused by the experimental drug known as danuglipron.
Pfizer Halts Obesity Pill Tests Amid Safety Concerns – Newser
Pfizer Halts Obesity Pill Tests Amid Safety Concerns Newser Pfizer ends development of potential pill obesity treatment CNN NVO, LLY, GPCR & VKTX Stocks Gain Following PFE’s Obesity Study Setback Yahoo Finance Pfizer Halts Obesity-Drug Development. What It Means for Eli Lilly, Novo Nordisk. Barron’s Pfizer scraps daily weight loss pill after liver injury in one patient CNBC